[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351838-105":59,"doc-detail-351838-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","mitf-driven-melanoma-plasticity-as-a-core-mechanism-of-therapy-resistance-integrating-microenvironmental-signaling-mechanotransduction-and-metabolic-reprogramming","MITF-Driven melanoma plasticity as a core mechanism of therapy resistance - integrating microenvironmental signaling, mechanotransduction, and metabolic reprogramming","","Melanoma remains a highly aggressive cancer, and durable benefit from immune checkpoint blockade and MAPK-targeted therapies occurs only in a subset of patients. This review explains how microphthalmia-associated transcription factor (MITF)-dependent phenotype switching enables melanoma cells to evade treatment through non-genetic, state-dynamic transitions. It integrates tumor microenvironmental inflammatory cues, mechanotransduction pathways, and metabolic rewiring, linking cytokines and hypoxia with fibroblasts, ECM remodeling, integrin-YAP/TAZ signaling, and glycolysis–OXPHOS and lipid/nutrient stress control.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mitf-driven-melanoma-plasticity-as-a-core-mechanism-of-therapy-resistance-integrating-microenvironmental-signaling-mechanotransduction-and-metabolic-reprogramming/351838/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mitf-driven-melanoma-plasticity-as-a-core-mechanism-of-therapy-resistance-integrating-microenvironmental-signaling-mechanotransduction-and-metabolic-reprogramming/351838.png","ImageObject",300,407,{"name":92,"@type":93},"Elsa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why do immune checkpoint blockade and MAPK-targeted therapies show durable responses only in some melanoma patients?","Question",{"text":113,"@type":114},"Durable responses are limited because most initially responding patients eventually develop resistance. The review attributes this resistance increasingly to non-genetic mechanisms, especially phenotypic plasticity and MITF-dependent phenotype switching.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What is MITF-dependent phenotype switching in melanoma?",{"text":118,"@type":114},"The review describes dynamic, non-genetic transitions between differentiated, proliferative, invasive, and drug-resistant phenotypes. Fluctuations in MITF activity enable reversible shifts among transcriptional and functional states.",{"name":120,"@type":111,"acceptedAnswer":121},"Which tumor microenvironmental signals regulate MITF states?",{"text":122,"@type":114},"The article integrates cytokine-driven inflammatory signaling and hypoxia with cancer-associated fibroblasts and extracellular matrix remodeling. These cues collectively shape MITF-dependent phenotype transitions and melanoma persistence under therapy pressure.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},351838,1790456364,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},137455077381,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","REVIEW ARTICLE     \nMITF-Driven melanoma plasticity as a core mechanism of therapy resistance: integrating microenvironmental signaling, mechanotransduction, and metabolic reprogramming  \nMonika Kisielewska a,b, Sara Suwała a,b, Małgorzata Drąg-Zalesińskac and Nina Rembiałkowska d  \naFaculty of Medicine, Wroclaw Medical University, Wroclaw, Poland; bStudent Research Group No. SKN148, Faculty of Pharmacy, Wroclaw Medical University, Wroclaw, Poland; cDepartment of Human Morphology and Embryology, Division of Histology and Embryology, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland; dDepartment of Molecular and Cellular Biology, Faculty of Pharmacy, Wroclaw Medical University, Wroclaw, Poland  \nABSTRACT  \nMelanoma remains one of the most aggressive cancers, and although immune checkpoint blockade and MAPK-targeted therapies have transformed clinical management, durable responses occur in only a subset of patients. Converging evidence identifies microphthalmia-associated transcription factor (MITF)– dependent phenotype switching as a central, non-genetic mechanism enabling melanoma cells to escape therapy. Dynamic fluctuations in MITF activity permit transitions between differentiated, proliferative states and invasive, drug-resistant phenotypes. This review synthesizes emerging insights into the tumor microenvironmental, mechanical, and metabolic cues that regulate MITF states. These include cytokine-driven inflammatory signaling, hypoxia, cancer-associated fibroblasts, extracellular matrix remodeling, integrin – YAP/TAZ – mediated mechanotransduction, and metabolic reprogramming involving glycolysis – OXPHOS switching, lipid-regulated MITF control, and nutrient-stress responses. By integrating these pathways, MITF-dependent plasticity shapes melanoma adaptation and persistence under therapeutic pressure. Understanding this interconnected network provides a foundation for developing strategies to target phenotype switching and overcome treatment resistance.  \nARTICLE HISTORY  \nReceived 19 January 2026 Revised 20 March 2026 Accepted 1 June 2026  \nKEYWORDS  \nMITF; melanoma; phenotype switching; therapy resistance; tumor microenvironment; mechanotransduction  \n1. Introduction  \nMelanoma is a highly aggressive skin cancer and remains a major global health challenge, with steadily rising incidence and mortality. According to GLOBOCAN 647 000 new cases and 58 645 deaths were reported worldwide in 2022 [1] . The introduction of ipilimumab in 2011, the first immune checkpoint inhibitor (ICI), marked a turning point in melanoma treatment, leading to a significant increase in overall survival [2] . Subsequent advances in targeted therapies, particularly v-Raf murine sarcoma viral oncogene homolog B (BRAF) and mitogen-activated extracellular kinase (MEK) inhibitors, have further expanded therapeutic options for advanced-stage disease. Nevertheless, durable responses remain limited because the majority of initially responding patients eventually develop resistance [3] . This resistance is increasingly attributed to non-genetic mechanisms, one of which is phenotypic plasticity [4] . Phenotypic plasticity refers to the capacity of melanoma cells to alter their phenotype in response to environmental or genetic changes. Cells exhibiting such plasticity may subsequently undergo phenotype switching, which describes dynamic transitions between distinct transcriptional and functional states. This process shares conceptual similarities with epithelial-mesenchymal transition (EMT), although phenotype switching in melanoma does not imply a directional or binary transition between two fixed states. Instead, melanoma cells can occupy multiple intermediate phenotypic programs and transition reversibly between them, conceptually resembling partial EMT states and the reverse process, mesenchymal-epithelial transition (MET), described in epithelial cancers [5,6] . This adaptive behavior is largely orchestrated through shifts in the expressi","cbCaidXMVk18XpdW","https://ap.wps.com/l/cbCaidXMVk18XpdW","pdf",2576147,22,"English","# Introduction\n## Phenotypic plasticity and phenotype switching\n## MITF regulation and the MITF rheostat model\n# Therapy resistance as a state-driven process\n## Microenvironmental cues (inflammation, hypoxia, fibroblasts, ECM remodeling)\n## Mechanotransduction (integrin – YAP/TAZ)\n## Metabolic reprogramming (glycolysis – OXPHOS, lipid and nutrient stress)","[{\"question\":\"Why do immune checkpoint blockade and MAPK-targeted therapies show durable responses only in some melanoma patients?\",\"answer\":\"Durable responses are limited because most initially responding patients eventually develop resistance. The review attributes this resistance increasingly to non-genetic mechanisms, especially phenotypic plasticity and MITF-dependent phenotype switching.\"},{\"question\":\"What is MITF-dependent phenotype switching in melanoma?\",\"answer\":\"The review describes dynamic, non-genetic transitions between differentiated, proliferative, invasive, and drug-resistant phenotypes. Fluctuations in MITF activity enable reversible shifts among transcriptional and functional states.\"},{\"question\":\"Which tumor microenvironmental signals regulate MITF states?\",\"answer\":\"The article integrates cytokine-driven inflammatory signaling and hypoxia with cancer-associated fibroblasts and extracellular matrix remodeling. These cues collectively shape MITF-dependent phenotype transitions and melanoma persistence under therapy pressure.\"}]","MITF-Driven melanoma plasticity as a core mechanism of therapy resistance - integrating microenvironmental signaling, mechanotransduction, and metabolic reprogramming | PDF",1790096261,55,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/717419da53da68c63df31c27d447b952.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4a8477825270be6cb1cc43a345194ce.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e62e48bf1071f3c15d310d6c9e28302.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/49572bd6b604d47cb8363229c63f6041.webp",980,1306]